CARROLL J MARTIN 4

What Happened

• Carroll J. Martin, a director of Esperion Therapeutics (ESPR), was granted 79,873 shares on May 28, 2026. The shares were issued at $0.00 (no cash paid); transaction code A (award/grant). The filing shows acquisition of the award but not an immediate sale.

Key Details

• Transaction date: 2026-05-28; Form 4 filed: 2026-06-01 (timely — within two business days).
• Price: $0.00 per share (grant); cash value shown in filing: $0.
• Shares owned after transaction: not specified in the provided filing.
• Vesting note (footnote F1): awards vest in full on the earlier of (i) May 28, 2027 or (ii) the issuer’s next annual meeting of stockholders following May 28, 2026.
• Transaction type: Award/Grant (not a market purchase or sale) — subject to vesting restrictions.

Context

• This is a director compensation grant, common for board service. Because the award is subject to vesting, it does not indicate immediate sale or straight cash investment by the insider. The filing was timely.